ACRUX LIMITED — Capital/Financing Update 2011

Sep 27, 2011

ACRUX (ACR) - ASX ANNOUNCEMENT

28 SEPTEMBER 2011

MARKET UPDATE

Acrux (ASX: ACR) Chairman Ross Dobinson today commented that coincidental with joining the S&P/ASX 200 index on 16 September, short selling has caused Acrux’s share price to fall. “We remain confident about the fundamentals of the business and about Axiron’s market performance, which was presented in detail by Acrux and Lilly on 23 August” he added.

The share of the United States testosterone therapy market captured by Axiron[®] continues to grow, with its share of New to Brand Prescriptions (NBRx) at 25.5% and its share of Total Prescriptions (TRx) at 7.5%.

Acrux’s revenues will be positively impacted if the sharp recent fall in the value of the Australian dollar against the US dollar is sustained, given that Acrux receives all Axiron royalties and milestone payments from Eli Lilly in US dollars.

“The US testosterone therapy market is still growing strongly and we are delighted with Axiron’s continuing market share gains”, commented Acrux CEO Richard Treagus. “We also confirm our guidance of 23 August that in the second quarter of 2011/12 we expect to confirm marketing approval of Recuvyra[®] in Europe and to provide an update on the pending 2026 patent for Axiron,” he added.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==